Webinar on Rational Predictions for FDA inspections

Overview:
The webinar covers factors considered by FDA before, during and after an inspection that can be used to predict your inspectional vulnerability. Once you know some key points, you will see that FDA's approach to inspections follows well-established procedures and risk criteria that enables FDA to characterize your firm's compliance. Usually the only way FDA will let you know about your profile is when an official action is indicated. That is not a good thing. Otherwise, you hear very little and even then, you may wait a long time. The cloud of doubt can plague a firm for months.

Why Should you Attend:

FDA's inspectional program is more predictable once you understand FDA's inspection selection criteria and the procedures used to conduct inspections. If you apply basic risk and public health concepts, the handwriting on the wall becomes clearer about the likelihood of an inspection. From an investigator's point of view, a firm's war room activity seems like a sequel to Shakespeare's play, "Much Ado about Nothing."

The investigators thinking and actions typically follow predictable directions and are usually based on information you already know. Whether or not an investigator will find your Pandora's Box of problems requires some skill in interpreting the first and second phase of an inspection. Firms are thinking along the lines of "Are they getting hot? Are they getting cold?" How can you tell? That actually is difficult to determine unless you identify the patterns in the investigator's work. Finally, firms invariably ask the investigator at the end of an inspection, "So how did we do?" You will not get an answer, but if you know how to read a list of inspectional observations noted on FDA's Form 483 (483), you can have a good idea.

Areas Covered in the Session:

FDA's annual work plan criteria for inspections
FDA's inspectional training and standard procedures
Evidence development strategy
War room hysteria
Inspection classification by FDA and follow up

Who Will Benefit:

Regulatory Affairs Directors / Managers
Corporate legal counsel
FDA consultants
Manufacturing Managers
Quality Assurance Managers

Speaker Profile:

Casper (Cap) Uldriks, through his firm “Encore Insight LLC,” brings over 32 years of experience from the FDA. He specialized in the FDA’s medical device program as a field investigator, served as a senior manager in the Office of Compliance and an Associate Center Director for the Center for Devices and Radiological Health. He developed enforcement actions and participated in the implementation of new statutory requirements. His comments are candid, straightforward and of practical value. He understands how FDA thinks, how it operates and where it is headed. Based on his exceptionally broad experience and knowledge, he can synthesize FDA’s domestic and international operational programs, institutional policy and thicket of legal variables into a coherent picture. Professional credentials: JD – Suffolk University, licensed in Massachusetts and the District of Columbia; M.Div in psychology – Boston University with internship through Harvard University.

Contact Detail:

NetZealous - Compliance4All,
161 Mission Falls Lane, Suite 216,
Fremont, CA 94539, USA.
Phone: +1-800-447-9407
Email: support@compliance4All.com
http://www.compliance4all.com/
Event Link : http://bit.ly/1GwxA9r